Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines

医学 比索洛尔 心绞痛 β受体阻滞剂 心力衰竭 心脏病学 心肌梗塞 血压 重症监护医学 疾病 内科学 原发性高血压
作者
Giuseppe Mancia,Sverre E. Kjeldsen,Reinhold Kreutz,Atul Pathak,Guıdo Grassı,Murray Esler
出处
期刊:Hypertension [Ovid Technologies (Wolters Kluwer)]
卷期号:79 (6): 1153-1166 被引量:69
标识
DOI:10.1161/hypertensionaha.122.19020
摘要

Several hypertension guidelines have removed beta-blockers from their previous position as first-choice drugs for the treatment of hypertension. However, this downgrading may not be justified by available evidence because beta-blockers lower blood pressure as effectively as other major antihypertensive drugs and have solid documentation in preventing cardiovascular complications. Suspected inconveniences of beta-blockers such as increased risk of depression or erectile dysfunction may have been overemphasized, while patients with chronic obstructive pulmonary disease or peripheral artery disease, that is, conditions in which their use was previously restricted, will benefit from beta-blocker therapy. Besides, evidence that from early to late phases, hypertension is accompanied by activation of the sympathetic nervous system makes beta-blockers pathophysiologically an appropriate treatment in hypertension. Beta-blockers have favorable effects on a variety of clinical conditions that may coexist with hypertension, making their use either as specific treatment or as co-treatment potentially common in clinical practice. Guidelines typically limit recommendations on specific beta-blocker use to cardiac conditions including angina pectoris, postmyocardial infarction, or heart failure, with little or no mention of the additional cardiovascular or noncardiovascular conditions in which these drugs may be needed or preferred. In the present narrative review, we focus on multiple additional diseases and conditions that may occur and affect patients with hypertension, often more frequently than people without hypertension, and that may favor the choice of beta-blocker. Notwithstanding, beta-blockers represent an in-homogenous group of drugs and choosing beta-blockers with documented effect in prevention and treatment of disease is important for first choice in guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qiqi发布了新的文献求助10
刚刚
5度转角应助fhy采纳,获得10
1秒前
sunjianyu完成签到,获得积分10
1秒前
家飞猫完成签到,获得积分10
1秒前
Owen应助ying采纳,获得10
2秒前
lutao完成签到,获得积分10
2秒前
小羽发布了新的文献求助10
2秒前
幸运小狗完成签到 ,获得积分10
3秒前
3秒前
3秒前
3秒前
3秒前
今后应助落后迎梦采纳,获得10
3秒前
cai完成签到,获得积分10
4秒前
葛儿发布了新的文献求助10
4秒前
4秒前
5秒前
今后应助jin采纳,获得10
5秒前
还单身的紫菜完成签到,获得积分20
5秒前
武巧运完成签到,获得积分10
5秒前
5秒前
橘生淮南完成签到,获得积分10
5秒前
乐乐应助H_Hou采纳,获得10
6秒前
6秒前
6秒前
6秒前
6秒前
pinecone发布了新的文献求助10
6秒前
7秒前
852应助爱笑的皮卡丘采纳,获得10
7秒前
7秒前
千西发布了新的文献求助10
8秒前
8秒前
9秒前
小二郎应助86采纳,获得30
9秒前
勤奋的清应助阿龙采纳,获得10
9秒前
爆米花应助hmz采纳,获得10
9秒前
9秒前
张晓林发布了新的文献求助30
10秒前
无花果应助烂漫的飞松采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6017229
求助须知:如何正确求助?哪些是违规求助? 7601593
关于积分的说明 16155238
捐赠科研通 5165029
什么是DOI,文献DOI怎么找? 2764811
邀请新用户注册赠送积分活动 1746022
关于科研通互助平台的介绍 1635112